Jazz registers Phase 3b/4 trial testing gradual CBD-OS titration in adult LGS patients
Jazz Pharmaceuticals has posted a new trial evaluating a slower titration schedule for its cannabidiol therapy in adults with Lennox-Gastaut Syndrome.
This week brought one new registry entry for Jazz Pharmaceuticals.
- Jazz Pharmaceuticals registered "EpiGOAL" (NCT07728097), a Phase 3b/4 open-label study of Cannabidiol Oral Solution (CBD-OS, also known as Epidiolex/Epidyolex) as add-on therapy in adults with Lennox-Gastaut Syndrome. The purpose of this study is to learn more about the efficacy of using CBD-OS as an add-on therapy for the treatment of LGS in adults.1 The trial is not yet recruiting, with an estimated enrollment of 40 participants and a planned start date of November 18, 2026; participants will be titrated up to a dose of 20 mg/kg per day or the maximum tolerated dose for 24 consecutive weeks.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.